An artificial intelligence system that operates like a collaborative team of medical experts could accelerate clinical trial ...

FDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell ...

Elizabeth Barnes, MS, RDN, LDN, is a registered dietitian specializing in eating disorders, type 2 diabetes, and heart health. Pair protein with complex carbs to get both quick and long-lasting fuel ...

Methods: A 12-week, parallel, single-blind randomized controlled trial was conducted with 123 participants (62/123, 50%, female; mean age 58.25 years, SD 9.46 years) recently diagnosed with T2D.

New human research reveals how gut bacteria and creatine may restore brain energy and improve depression. If you have or know ...

Abstract: Safety and data efficiency are important concerns in data-driven control, especially for nonlinear systems with unknown dynamics and subject to disturbances. In this work, we consider a ...

The objective of this cluster randomized controlled trial was to determine the feasibility and safety of an intensive (systolic blood pressure [SBP] <120 mm Hg) versus usual care (SBP <140 mm Hg) ...

Whole-blood transfusion has recently gained favor in the management of severe hemorrhage; however, data from large clinical trials evaluating its clinical effectiveness and safety are lacking. We ...

Average current-mode control, as shown in Figure 1, is common in continuous-conduction-mode (CCM) power factor correction (PFC). It has two loops: a voltage loop that works as an outer loop and a ...

This 40sqm cabin, known as The Pod, is designed as a complete living system. Every function — sleeping, cooking, working — is integrated with precision. Instead of space, the design prioritizes ...

A new study in the American Journal of Preventive Medicine reports findings from a randomized controlled trial—the gold standard study design in health research—showing that promoting drinking water ...

The FDA is raising the bar for approval of CAR T-cell therapies in oncology. Under plans outlined by the FDA’s biologics chief Vinay Prasad, M.D., the agency will require developers of many CAR-Ts to ...